HuiKai Medical Completes Tens of Millions RMB Series A+ Financing to Accelerate Clinical Trials of Novel Urethral Stent System

VCBeat has learned that Shanghai Huikai Medical Technology Co., Ltd. (“Huikai Medical”) has recently completed a tens-of-millions-of-RMB Series A+ financing round, exclusively invested by Beijing Natong Technology Group (“Natong Group”). The proceeds will be used to support the clinical development and market promotion of Huikai Medical’s core products.

HUIKAI, established in December 2018, is a platform-based medical device company specializing in urology. Its product portfolio spans multiple subfields, including benign prostatic hyperplasia (BPH), stone management, urinary incontinence, urological tumors, and new materials. The company has established an R&D center in Suzhou, as well as a clinical trial base and a Central China marketing center in Wuhan. HUIKAI completed its angel financing round in 2019 and secured tens of millions of RMB in Series A financing from Furong Investment and YuanBio Venture Capital in 2021.

HUIKAI leverages interventional devices, high-performance materials, and precision manufacturing as its technological foundation. With independent intellectual property rights, the company is dedicated to the research, development, and production of minimally invasive diagnostic and therapeutic instruments for the urinary system that are more suitable, safer, and more efficient. The founding team brings years of experience in product development and clinical practice within the healthcare industry, offering extensive expertise and a forward-looking perspective.

In terms of R&D, HUIKAI adheres to the integration of medicine and engineering, inviting urology experts to participate deeply in product development. All research directions are closely aligned with clinical practice, identifying problems and unmet real-world needs from clinical settings. Through multidimensional research encompassing theory, technology, methodology, and practice, and leveraging engineering approaches, the company ultimately achieves a closed loop that returns to clinical application.

Its core product, UroStent^®It is a prostate stent system that requires neither general anesthesia nor cystoscopic guidance for positioning and deployment. The system is user-friendly, allowing the operator to complete implantation within five minutes, significantly reducing preoperative preparation and procedural time, thereby enabling day-case or outpatient surgery.

Currently, UroStent^®Clinical trials have been initiated at Sun Yat-sen Memorial Hospital, Sun Yat-sen University.

For this round of financing,Cheng Guozheng, Founder and General Manager of HUIKAIThe statement read: “We extend our heartfelt gratitude to both new and existing shareholders for their trust and support in HUIKAI. The completion of this financing round marks the beginning of a new chapter in HUIKAI Medical’s development. Against the backdrop of an increasingly aging population, we will intensify our focus on R&D investment and market expansion, always guided by the clinical needs of doctors and patients, striving to provide surgical solutions that are more suitable, safer, and minimally invasive. HUIKAI Medical is honored to have gained recognition from prominent industrial capital. We remain steadfast in advancing the clinical translation and application of minimally invasive interventional procedures in urology. With the support of Naton Group, HUIKAI Medical is confident that our innovative technologies will foster the development and progress of urology.”

Li Zhengxiong, Executive General Manager of Furong InvestmentStatement: As the lead investor in the previous funding round, we welcome Natong Group’s strategic investment in HUIKAI. Over the past year, the HUIKAI team overcame various challenges posed by pandemic-related lockdowns and efficiently advanced the First-in-Human (FIM) clinical trial of the UroStent system as well as the R&D of multiple innovative products, which was no easy feat. With the rapid aging of the population, we are optimistic about the market potential in the urology sector and will continue to fully support the company’s development.

Naton GroupHUIKAI’s core product, the urethral stent, is a result of medical-engineering translation. It optimizes relevant surgical procedures, reduces surgical requirements and operational complexity, and aligns with the trends of an aging population, outpatient-based care, and primary-care accessibility. Moreover, the company has a comprehensive product portfolio in the urology field. We are optimistic about HUIKAI’s future development and are pleased to be part of its journey. We hope that the company’s products will reach the market soon to benefit a wide range of patients.

Furong Investment, established in 2014, is a specialized innovation investment and service firm focused on early- to mid-stage projects in life and health, semiconductors, new energy materials, and other fields. Adhering long-term to the principles of “research-driven” and “early-stage, specialized investing,” it is committed to promoting the industrialization of scientific and technological achievements and fostering innovation and entrepreneurship among high-level talent. It actively supports national innovation-driven development strategies, including the integrated development of the Yangtze River Delta region and Shanghai’s initiative to build a globally influential science and technology innovation hub.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. To date, YuanBio has invested in over 160 outstanding companies in the life and health sectors, covering four key areas: innovative drug development, medical devices, in vitro diagnostics (IVD) and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 18 of its portfolio companies having listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Beijing Natong Technology Group is an international medical and healthcare industry group that integrates independent R&D, large-scale manufacturing, specialized marketing, and high-quality medical service applications. The Group’s core business spans medical implants, intelligent surgical devices, bio-based materials, and epidemic prevention supplies, and it owns 11 national high-tech enterprises.

Naton Group upholds its mission of “advancing medical technology, leading the development of the healthcare industry, and helping patients overcome diseases and restore health at minimal cost,” and remains committed to providing high-quality medical products and technical services to society. Since its establishment, Naton Group has been successively recognized as an “Outstanding Contributor Enterprise and Industry Leader in Beijing’s G20 Project for Leapfrog Development of the Biopharmaceutical Industry,” a “National Enterprise Technology Center,” one of the “Top 100 Private Enterprises in Beijing,” an “Advanced Collective in Beijing’s Fight Against the COVID-19 Pandemic,” an “Advanced Collective Contributing to the Comprehensive Building of a Moderately Prosperous Society by Democratic Parties, Federations of Industry and Commerce, and Non-partisan Individuals,” a “National Advanced Private Enterprise in Employment and Social Security,” and a “National Intellectual Property Demonstration Enterprise.”